原发性胆汁性胆管炎（primary biliary cholangitis,PBC）是一种慢性自身免疫性肝内胆汁淤积性疾病，多见于中老年女性，早期可无症状，临床常见为乏力和皮肤瘙痒等症状。疾病的早期识别和及时治疗对其预后非常重要。本文介绍了PBC的诊疗要点，以供参考。

作者：陈洁，王雪，李春燕，汤善宏西部战区总医院消化内科自身免疫性肝病（autoimmune liver disease，AILD）主要由包括以肝细胞损伤为主的自身免疫性肝炎（autoimmune hepatitis，AIH）、以胆管细胞损伤为主的原发性胆汁性胆管炎（primary biliary cholangitis，PBC）及原发性硬化性胆管炎（primary sclerosis cholan ...

文章中，研究者发现，名为万古霉素（vancomycin）的抗生素或能有效治疗患有特定类型炎性肠病（IBD）的患者，这种疾病会在一种无法治愈的称之为原发性硬化性胆管炎（PSC，primary sclerosing ...

Objectives Primary sclerosing cholangitis (PSC) is a rare chronic disease that presents challenges to both patients and clinicians. This study aimed to explore the experiences of patients with PSC ...

Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing ...

Primary sclerosing cholangitis (PSC) is a progressive scarring of the liver's bile ducts. According to current estimates, between 5 and 16 in every 100,000 people have PSC. The symptoms of PSC ...

Oral vancomycin therapy resulted in clinical response in nearly half of patients with inflammatory bowel disease associated ...

(GILD) announced that the European Commission has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis in combination with ursodeoxycholic ...

Gilead Sciences (GILD) said on Friday that the European Commission (EC) granted conditional marketing authorization for ...

Gilead Sciences, Inc. has received conditional marketing authorization from the European Commission (EC) for Seladelpar for the treatment of primary biliary cholangitis (PBC) ...

Primary Biliary Cholangitis Clinical Trial Pipeline Pharmaceutical companies are advancing the Primary Biliary Cholangitis treatment pipeli ...

(Nasdaq: GILD) today announced that the European Commission (EC) has granted conditional marketing authorization for seladelpar for the treatment of primary biliary cholangitis (PBC) in ...